Imported human African trypanosomiasis in Europe, 2005-2009 by Gautret, P et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Imported human African trypanosomiasis in Europe, 2005-2009
Gautret, P; Clerinx, J; Caumes, E; Simon, F; Jensenius, M; Loutan, L; Schlagenhauf,
P; Castelli, F; Freedman, D; Miller, A; Bronner, U; Parola, P
Gautret, P; Clerinx, J; Caumes, E; Simon, F; Jensenius, M; Loutan, L; Schlagenhauf, P; Castelli, F; Freedman, D;
Miller, A; Bronner, U; Parola, P (2009). Imported human African trypanosomiasis in Europe, 2005-2009. Euro
Surveillance , 14(36):1-3.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Euro Surveillance 2009, 14(36):1-3.
Gautret, P; Clerinx, J; Caumes, E; Simon, F; Jensenius, M; Loutan, L; Schlagenhauf, P; Castelli, F; Freedman, D;
Miller, A; Bronner, U; Parola, P (2009). Imported human African trypanosomiasis in Europe, 2005-2009. Euro
Surveillance , 14(36):1-3.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Euro Surveillance 2009, 14(36):1-3.
Imported human African trypanosomiasis in Europe, 2005-2009
Abstract
Physicians in Europe are likely to see more African trypanosomiasis cases because of the increasing
popularity of travel to Africa. In this paper the literature on imported cases in Europe, since 2005 is
reviewed. Because of the high mortality risk associated with acute Rhodesian trypanosomiasis, travellers
should be informed about preventive measures and the early disease manifestations.
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Physicians in Europe are likely to see more African trypanosomiasis 
cases because of the increasing popularity of travel to Africa. In 
this paper the literature on imported cases in Europe, since 2005 
is reviewed. Because of the high mortality risk associated with 
acute Rhodesian trypanosomiasis, travellers should be informed 
about preventive measures and the early disease manifestations.
Introduction
Human African trypanosomiasis (HAT) is endemic in sub-
Saharan Africa. Trypanosoma brucei rhodesiense (East Africa) and 
T. b. gambiense (West Africa) are transmitted to humans by tsetse 
flies of the Glossina morsitans group (T. b. rhodesiense) and of the 
G. palpalis group (T. b. gambiense) which are found only in Africa. 
West African sleeping sickness has almost exclusively a human 
reservoir, while East African trypanosomiasis is a zoonosis involving 
antelopes, cattle and humans. Infections by both T. b. gambiense 
and T. b. rhodesiense are generally under-reported in humans 
due to acuteness and lack of specific symptoms at the onset of 
disease as well as its rural distribution. T. b. rhodesiense is focally 
endemic in many eastern and southern African countries. It tends 
to occur in form of epidemic outbursts. Human infections have 
been reported mainly from Malawi, south-east and central Uganda 
and Tanzania, and sporadically from Kenya, Mozambique, Rwanda, 
Zambia and Zimbabwe. T. b. gambiense, the parasite causing West 
African sleeping sickness is focally endemic in Angola, Democratic 
Republic of the Congo, Central African Republic, Chad, Republic 
of the Congo, Côte d’Ivoire, Guinea, southern Sudan and north-
west Uganda. Cases have been sporadically reported from Burkina 
Faso, Cameroon, Equatorial Guinea, Gabon, Nigeria, Benin, Ghana 
and Mali [1]. All countries listed so far have a surveillance system 
for HAT, however, there is no dedicated structure for surveillance 
in Burundi, Ethiopia, Gambia, Guinea-Bissau, Liberia, Niger, 
Senegal and Sierra Leone, where under-reporting may be likely 
[2]. A new HAT atlas initiative for sub-Saharan Africa has led to the 
creation of a geographic database to store and regularly update HAT 
epidemiological data. The resulting detailed, high quality regional 
level maps allow the geo-location of autochtonous cases that have 
been detected through active and passive surveillance [3].
HAT has always been an exceptional travel-associated disease. 
It is a rare cause of fever [4] cutaneous lesions and/or neurological 
signs in travellers returning from endemic areas. Although it has 
been estimated that about 50 cases are reported yearly outside 
Africa [5], no recent estimate is available. In Europe, the largest 
published data on imported HAT included 109 cases registered 
between 1904 and 1963 [6]. Over the last decades, 26 cases 
(including 24 West African HAT) seen in France between 1980 and 
2004, were reviewed [7]. In addition, imported cases were reported 
in Italy [8,9], Spain [10], the United Kingdom [11-13], Germany 
[14], the Netherlands [15-19], Belgium [20], Norway and Sweden 
[21,22], Switzerland [23], Poland [24] and France [25-26].
We present the clinical and epidemiological characteristics of 
published HAT cases imported in Europe since 2005 (Table). 
Diagnosis
T. b. gambiense represents more than 90% of all reported 
cases of HAT worldwide (autochthonous and imported cases) 
but T. b. rhodesiense accounts for 60% of imported cases.
T. b. rhodesiense infection in humans is characterised by high 
grade fever, an inoculation chancre and substantial parasitaemia in 
its acute stage. Incubation period is about 6 to 10 days, but may 
be as short as three days. Gambian HAT may follow an indolent 
course with a very low or absent parasitaemia. It may remain 
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unrecognised for years [5]. T. b. gambiense is better adapted 
to its human host, allowing humans to be infective for extended 
periods thereby sustaining its endemicity. In active infection, 
T. b. gambiense and T. b. rhodesiense specific IgG and IgM 
antibodies are present in high concentration and can be detected by 
ELISA or immunofluorescence from about three to four weeks after 
infection. Parasite detection using blood concentration techniques 
should be done to confirm the infection. Furthermore, in 60% 
of infections with T. b. gambiense, parasites can be detected in 
lymph aspirate from enlarged cervical nodes. Cerebrospinal fluid 
examination is always required to evaluate neurological involvement 
which determines the choice of therapy [5]. 
Implications for travellers
Whereas imported HAT due to T. b. gambiense is more often 
seen in migrants and expatriates residing in rural endemic areas, 
HAT due to T. b. rhodesiense is more likely to be seen in travellers 
to East African game parks where the ungulate wildlife serves as a 
reservoir for the pathogen. In recent years almost all reported cases 
have been infected in northern Tanzania (Serengeti, Tarangire) or in 
Uganda (Queen Elizabeth National Park) [17,18,22,24,28]. Some 
emerging tourist destinations (Malawi: Kasungu National Park, 
Waza Game Reserve; Rwanda: Akagera National Park; Zambia: 
South Luangwa National Reserve; Tanzania: Moyowosi Game 
Reserve) are known foci of T. b. rhodesiense, and may pose a risk 
for travellers.
In travellers infected with T. b. rhodesiense, an evolving chancre 
on the bite site precedes the onset of high grade fever, and usually 
persists for a few days thereafter. This is an important clinical 
sign not to be missed by the attending physician. Fulminant 
disease progression has been reported in a German tourist in her 
forties with a history of tsetse bites during a visit to the Serengeti 
National Park. She died only six days after fever onset (13 days 
following tsetse bites), in Nairobi Hospital, after air ambulance 
evacuation from a private clinic in Dar es Salaam where the HAT 
diagnosis was made. She had two typical chancres that were missed 
when she first presented with fever in another clinic seven days 
after the tsetse bites, and a malaria diagnosis was alleged [29]. 
A history of tsetse fly bites in patients with clinical symptoms 
has to be considered a medical emergency. Early treatment with 
suramin (Germanin®, Bayer 205) or in case of non-availability, 
with pentamidine is essential to prevent severe complications and 
death. All available drugs for HAT treatment, including suramin 
can be obtained through the World Health Organization (WHO) 
trypanosomiasis control and surveillance unit, by contacting Dr. 
Simarro (simaropp@who.int) and Dr. Franco (francoj@who.int). A 
small stock of HAT drugs should be made available at one tropical 
medicine/travel medicine centre per country, in order to enable 
early treatment when required.
T a b l e 
Imported cases of African trypanosomiasis in Europe, since 2005, by date of publication
Sex Age Nationality Clinical features(time before first symptoms and diagnosis)
Sub-
species
Country of exposure 
(reason for travel) Treatment
Reference 
( year)
M 44 Italian
Fever, headache, fatigue, weight loss, paresthesia, day-time 
somnolence, insomnia, hepatosplenomegaly, lymph nodes, ataxia 
(6 months)
gambiense
Gabon
(expatriate)
Eflornithine 9 (2005)
F 54 Italian
Fever, headache, fatigue, splenomegaly, insomnia, hyperesthesia 
(3 months)
gambiense
Central African 
Republic
(expatriate)
Eflornithine 9 (2005)
F 52 Dutch
Fever, headache, vomiting, diarrhea, confusion, depression, 
hallucinations, sleepiness. One relapse episode. Death. 
(4 days)
rhodesiense
Serengeti national 
park of Tanzania 
(tourist)
Suramin, 
Melarsoprol
17 (2006)
M 37 French
Fever, fatigue, anorexia, headache, arthralgia, insomnia, rash, 
pruritus, paresthesia, lymph nodes, weight loss 
(8 months)
gambiense
Gabon, Camerron, 
Guinea (expatriate)
Pentamidine 26 (2007)
M 72 French
Fever, fatigue, pruritus, lymph nodes, weight loss 
(5 months)
gambiense
Gabon 
(expatriate)
Pentamidine 26 (2007)
M 26 British
Fever, insomnia, lethargia, vomiting chancre, erythema, jaundice 
(5 days)
rodhesiense
Malawi
(military)
Suramin 12 (2007)
M 38 British
Fatigue, somnolence, headache, fever, lymph nodes, hepatomegaly, 
myalgia. One relapse episode. 
(4 months)
rhodesiense
Namibia, Mozambique, 
Malawi 
(unknown reason, 
travel for 2.5 years)
Suramin, 
Melarsoprol
13 (2007)
F 25 Dutch
Fever, headache, cellulitis, red papule, lymphangitis 
(4 days)
rhodesiense
Serengeti National 
park of Tanzania 
(tourist)
Suramin 18 (2009)
M 61 Polish
Fever, jaundice, respiratory distress, bleeding (disseminated 
intravascular coagulation - DIC), oliguria, skin rash, 
hepatosplenomegaly 
(8 days)
rhodesiense
Queen Elizabeth 
national park of 
Uganda 
(tourist)
Pentamidine 24 (2009)
M 50 French
Fatigue, fever, double skin ulceration, lymph nodes 
(7 days)
gambiense
Gabon 
(expatriate)
Pentamidine 27 (2009)
F 27
Dutch 
(immigrant 
from Angola)
Fatigue, apathy, sleepiness, loss of apetite, depression, coma 
(32 months)
gambiense
Angola 
(immigrant)
Eflornithine 19 (2009)
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Conclusions
Physicians in Europe are likely to see more HAT cases because 
of the increasing popularity of travel to Africa, the only region 
that has recorded a growing number (3%) of tourist arrivals in 
2009 according to the United Nations World Tourism Organization 
(UNWTO, www.unwto.org). The average annual growth of tourism 
in some sub-Saharan countries such as Tanzania and Uganda 
has ranged between 10 and 20% with a focus on safari travel. 
Because of the high mortality risk associated with acute Rhodesian 
trypanosomiasis, European travellers to destinations where the 
disease is endemic, particularly game parks and safari areas 
in eastern and southern Africa, should be informed about the 
early disease manifestations and advised to report tsetse bites 
to their physician upon return, when presenting symptoms. 
Although thousands of travellers are bitten by tsetse flies each 
year, the majority will not develop HAT. Nevertheless, caution is 
recommended. Preventive measures against tsetse fly bites are 
helpful. The tsetse fly is active during the daytime and is particularly 
attracted by motion and dark colours, with a marked preference 
for blue. Bites are painful and can be prevented by wearing wrist- 
and ankle-length clothing of thick material and avoiding bright 
or contrasting coloured clothing. Because the tsetse fly is able 
to bite through thinly woven fabric, the impregnation of clothing 
with permethrin is recommended together with the application of 
a skin repellent [30].
At present, imported HAT cases are not systematically reported 
through the existing channels to signal emerging infections 
(ProMED) or in the accessible medical literature. To harmonise 
reporting, we would recommend the creation of an electronic 
reporting form. This would allow for the evaluation of long term 
trends in imported HAT, and contribute to identifying risk factors 
and risk areas.
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